Background:Melasma is a persistent acquired hypermelanosis of the skin, described by muddy brown coloured macules evenly disseminated on sunexposed region of the body, especially on the face. The present study was conducted to assess the oral versus intradermal Tranexamic acid infusion for the treatment of melasma. Materials & Methods:100 patients of melasma of age group 20 to 45 years were assigned to 2 groups – Oral (Group A) and intralesional (Group B). Patients in the oral therapy group were given tablet tranexamic acid (250 mg) twice daily for 3 months. In the intralesional group, patients were administered intradermal injections of tranexamic acid. Clinical assessment of patient was performed using modified MASI score. Results: Pattern was Centrofacial in 23 and 20, mandibular in 17and 18 and dermal in 10 and 12 patients in group I and II respectively. Type was dermal in 8 and 8, and epidermal in 17 and 16 patients and mixed in 25 and 26patients. Fitzpatrick skin type II was seen in 5 and 6, III in 25 and 22, and IV in 20 and 22 patients in group I and II respectively. The difference was non- significant (P> 0.05). In group I and group II, the mean MASI score at 1st sitting was 4.478 and 4.468, at 2nd sitting was 3.402 and 3.476 ± 2.2806, at 3rd sitting was 2.712 ± 1.7784 and 2.736 ± 1.847, at 4th sitting was 2.04 ± 1.3334 and 2.076 ± 1.4353, at 5th sitting was 1.784 ± 1.2079 and 1.84 ± 1.2886 and at 6th sitting was 2.07 ± 1.8486 and 2.052 ± 1.8655respectively. The difference was significant (P< 0.05). Conclusion: Tranexamic acid is safe and well tolerated drug for the treatment of melasma. Both intradermal and oral modes of administration are effective for melasma. We observed a significant decrease in the mean MASI scores from 1st sitting to 5th sitting in both Group 1 and Group 2, showing an improvement in their melasma severity over time. However, when comparing the two groups, there were no significant differences in the extent of this improvement, as the MASI scores remained similar between the groups across all sittings.